Kiora Pharmaceuticals appoints Carmine Stengone to Board of Directors

KIORA PHARMACEUTICALS INC

Carmine Stengone (President & CEO of Pipeline Therapeutics) appointed as independent Class I director; term to 2025 annual meeting.
Stengone raised >$180M and executed a >$1B collaboration with Janssen; expertise in small molecules and neurodegenerative diseases.
He will advise on strategic decisions and clinical development, notably for KIO-301 (retinitis pigmentosa candidate in ABACUS trial).
Board determined independence under Nasdaq rules; compensation same as other non-employee directors.
No arrangements, family relationships, or material transactions with the company since start of last fiscal year.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Carmine Stengone

Director

KPRX · KIORA PHARMACEUTICALS INC

Effective: 2023-08-01
Filed: August 1, 2023, 7:59 PM ET

On August 1, 2023, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Carmine Stengone as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Carmine Stengone was appointed as Director at KIORA PHARMACEUTICALS INC.

Action: appointed
Role: Director

Exact text from the filing

On August 1, 2023, the Board of Directors (the “Board”) of Kiora Pharmaceuticals, Inc. (the “Company”) appointed Carmine Stengone as a member of the Board.

View on SEC.gov

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-23-000112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.